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abstract
Objective: To compare the effectiveness of two different pharmacy-based 
colorectal cancer screening (CRCS) interventions taking place during an annual influ-
enza vaccination campaign. 
Design: Time randomized clinical trial. 
Setting: San Francisco, CA, in late 2008.
Participants: 133 adults aged 50 to 80 years visiting a pharmacy during an influ-
enza vaccination campaign and also due for CRCS.
Intervention: On five dates, eligible patients were provided education and en-
couraged to obtain screening from their primary care clinician. On 17 dates, a home 
fecal immunochemical test (FIT) for CRCS was provided. A 16-item questionnaire 
was administered by phone 3 to 6 months after study enrollment.
Main outcome measure: Self-reported CRCS activity, comparing CRCS comple-
tion rates for participants provided with the FIT versus those provided with education 
and encouragement to obtain screening from patients’ primary care clinician. 
Results: 86 participants in the FIT arm and 28 the CRCS education arm were in-
terviewed. Interviews revealed that 19.8% of the FIT group and 50% of the CRCS edu-
cation group discussed CRCS with their primary care clinician (P = 0.002). Of these 
participants, 59.3% in the FIT arm and 14.8% in the CRCS education arm reported 
completing screening (P < 0.001). Of participants in the FIT group, 52.2% completed 
FIT dispensed to them by the investigators. Most participants in both groups reported 
interest in receiving CRCS education and home CRCS tests from pharmacists in the 
future. 
Conclusion: Pharmacy patients are receptive to CRCS interventions delivered in 
community pharmacies. Providing FIT to eligible patients during a pharmacy-based 
influenza vaccination campaign increases screening rates more than CRCS education 
alone.
Keywords: Colorectal cancer, health screening, community pharmacists, fecal 
occult blood tests, influenza vaccine, patient education.
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Colorectal cancer screening (CRCS) can prevent most colorectal cancer deaths.1 However, less than two-thirds of Americans are getting screened, and colorectal can-
cer remains the second leading cause of cancer mortality in 
the United States.2,3 The U.S. Preventive Services Task Force 
(USPSTF) recommends CRCS for all individuals beginning at 
age 50 years and continuing at least until 75 years, as this is 
the population of average-risk individuals most likely to benefit 
from screening.4 USPSTF recommends three different CRCS 
options: (1) fecal occult blood testing with high-sensitivity 
guaiac tests or fecal immunochemical tests (FITs) annually, 
(2) sigmoidoscopy every 5 years with guaiac test or FIT every 
3 years, or (3) colonoscopy every 10 years. A decision analy-
sis by USPSTF concludes that all three of these approaches to 
screening are equivalent in terms of their potential to reduce 
colorectal cancer mortality for average-risk individuals when 
done on time with appropriate follow-up.5 Among these tests, 
annual high-sensitivity guaiac test and FIT are effective, nonin-
vasive, inexpensive, and could be provided in U.S. pharmacies.
The principal of both types of home fecal occult blood tests 
(guaiac test and FIT) is that yearly testing can detect intermit-
tent bleeding from slow-growing precancerous polyps or early 
cancers that can be confirmed with colonoscopy and removed 
before they become life threatening.6 Guaiac tests detect per-
oxidase activity of heme in stool using a hydrogen peroxide de-
veloper. The tests require dietary and medication restrictions 
to ensure accurate results. The most sensitive guaiac tests re-
quire taking a total of six samples of stool from three bowel 
movements. High-sensitivity guaiac tests have a reported sen-
sitivity of 64% to 80% for colorectal cancer.4 FITs use specific 
antibodies to human blood components such as the globin pro-
tein portion of human hemoglobin and therefore do not require 
dietary or medication restrictions. FITs have a reported sensi-
tivity of 61% to 90% for colorectal cancer.4 Lower-sensitivity, 
“throw-in-the-bowl” versions of the guaiac test have been sold 
in U.S. pharmacies but have not been evaluated or recom-
mended for use by USPSTF. A variety of home fecal occult blood 
tests, including FIT, are sold in pharmacies in countries other 
than the United States, however.7
Every year, pharmacists administer hundreds of thou-
sands of influenza vaccinations in the community pharmacy 
setting.8–12 Many individuals who get influenza vaccinations in 
pharmacies are likely also due for CRCS. Based on evidence 
that a hospital-based influenza vaccine clinic can offer an op-
portunity to provide CRCS education and access to home fe-
cal occult blood test kits to patients outside of the context of 
primary care, the investigators wished to explore the use of a 
similar intervention in community pharmacies.13
Objective
The goal of this pilot study was to assess the feasibility of pro-
viding a CRCS intervention to patients during influenza vacci-
nation clinics held in community pharmacy settings. Specifi-
cally, the objective was to compare the effectiveness of provid-
ing eligible individuals with FIT versus an intervention consist-
ing of CRCS education with encouragement to obtain CRCCS 
from their primary care clinician. Outcomes were assessed by 
phone interviews with study participants 3 to 6 months after 
the intervention.
Methods
The study took place at a large nationwide community chain 
pharmacy with stores in diverse San Francisco, CA, neigh-
borhoods. These pharmacies provide an annual, in-store, 
pharmacist-administered influenza vaccination program by 
appointment and walk in. A total of 18 pharmacies located in 
different areas of the city were selected for participation based 
on recommendations of the regional pharmacy manager and 
factors such as available space to perform the intervention and 
potential volume of English-speaking patients in the targeted 
age group. All of the pharmacies contacted agreed to partici-
pate. The study was approved by the University of California at 
San Francisco Institutional Review Board.
The study used a time-randomized design. In consultation 
with the researchers, each of the 18 pharmacies selected one 
or two influenza vaccination sessions lasting 4 to 6 hours each, 
during which the researchers could visit and conduct the study. 
The researchers created a schedule consisting of 22 sessions 
At a Glance
Synopsis: The current study demonstrated that 
providing home colorectal cancer screening (CRCS) 
tests in the community pharmacy setting to eligible pa-
tients at the time of influenza vaccination can increase 
screening rates compared with providing CRCS educa-
tion only. Patients were divided into two arms: a fecal 
immunochemical test and a CRCS education arm. Of 
participants interviewed 3 to 6 months after the inter-
vention, 19.8% of the FIT group and 50% of the CRCS 
education group reported discussing CRCS with their 
primary care clinician. Completion of screening was 
reported by 59.3% in the FIT group and 14.8% in the 
CRCS education group. Participants in both groups ex-
pressed enthusiasm for CRCS interventions delivered 
in community pharmacies.
Analysis: The current results indicate that phar-
macy-based CRCS education can be successful in en-
couraging patients to discuss CRCS with their primary 
care clinicians but that offering FIT to patients in phar-
macies may lead to greater increases in screening dur-
ing a 3- to 6-month period compared with pharmacy-
based education alone. The majority of participants 
indicated an intention to obtain influenza vaccinations 
at their community pharmacy again in the future, sug-
gesting that annual pharmacy-based influenza vacci-
nation clinics may provide good opportunities for phar-
macists to reach specific groups of individuals with 
other important and personalized annual preventive 
health messages or interventions such as those relat-
ing to CRCS.
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in October and November 2008, with one or two pharmacies 
participating on any given date. Each 4- to 6-hour session was 
randomized so that all patients in a given session were allo-
cated to one of two interventions: FIT or CRCS education. Phar-
macy customers were allowed to participate in the study re-
gardless of whether they were in the pharmacy to get a vaccine.
Initially, a one-to-one randomization scheme was planned, 
but because of low pharmacy customer volume during the ses-
sions selected in the first week, the allocation of the two in-
terventions was changed to a four-to-one randomization. This 
change was made to maximize exposure to and experience with 
the FIT intervention. One to three members of the research 
team were present at each site on the day of the intervention. 
Potential study participants were approached by a member of 
the research team as they were waiting for their influenza vac-
cination, with eligibility determined by asking patients’ age and 
the date and type of their last CRCS test. Patients were con-
sidered eligible for the intervention if they were both of aver-
age risk for colorectal cancer and due for screening, which was 
defined as age between 50 and 80 years with no colonoscopy 
in the previous 10 years, no home fecal occult blood test in the 
previous year, no personal or family history of colorectal can-
cer, and no history of inflammatory bowel disease. Consistent 
with USPSTF and other national guidelines, individuals who re-
ported flexible sigmoidoscopy in the previous 5 years were not 
automatically excluded, and neither were older adults between 
75 and 80 years of age who reported being in generally good 
health. Potential study participants who could not speak Eng-
lish or who had no primary care source to which test results 
could be sent or to which they could receive recommended fol-
low-up were excluded. Informed consent was obtained from all 
eligible and interested participants. Eligibility and enrollment 
activities took place at a table located a few feet from the influ-
enza vaccine station in the participating pharmacy. Sociode-
mographic data collected at enrollment included age, gender, 
ethnicity, educational level, health insurance status, history of 
receiving an influenza vaccination, and history of receiving a 
CRCS test.
In the FIT group, participants received a FIT kit (Enterix 
InSure—Quest Diagnostics) with brief counseling by a member 
of the research team on how to use the test and why screening 
is important. Participants were asked to complete the FIT and 
mail it to Quest Diagnostics. Test results were sent to the prin-
cipal investigator, who then notified the patient and patient’s 
designated primary care clinician of the results. Participants 
in the CRCS education group were provided with a two-page 
educational handout that was reviewed with the patient by a 
member of the research team. Patients in the CRCS education 
group were instructed to contact their primary care clinician 
to obtain CRCS. A reminder telephone call was made to each 
participant between 3 and 6 weeks after receiving the interven-
tion, and each participant was encouraged to complete the FIT 
kit or contact their primary care clinician, depending on the 
study arm in which they were enrolled.
Approximately 3 to 6 months after the intervention, investi-
gators interviewed participants by phone to complete a 16-item 
survey assessing self-reported CRCS activity and attitudes to-
ward the pharmacy-based CRCS service. The primary study 
outcome was self-reported CRCS activity (i.e., whether any 
type of CRCS test was completed). In the FIT group, completion 
of FIT was corroborated with results from the lab. Survey items 
for the CRCS education group included whether the partici-
pant remembered receiving written information about CRCS 
at the pharmacy during their influenza vaccination, whether 
the information was considered useful, whether the partici-
pant visited their primary care clinician and discussed CRCS 
since enrolling in the study, and whether CRCS was scheduled 
or completed. Survey items for the FIT group included whether 
the participant remembered receiving a home stool test at the 
pharmacy during their influenza vaccination, if the FIT was 
completed and reasons why or why not, their experience with 
using FIT, and whether the participant had seen their primary 
care provider and discussed CRCS since enrolling in the study. 
Both groups were asked whether they thought it was a good 
idea and helpful for community pharmacists to educate pa-
tients about CRCS and offer a CRCS test when indicated. Last, 
all participants were asked the amount of money they would 
be willing to pay out of pocket for such a test. The interview 
surveys are presented in Appendix 1 (electronic version of this 
manuscript, available online at www.japha.org).
Data analysis
Statistical analyses were performed using SAS (version 9.2; 
SAS, Cary, NC). Demographic and questionnaire data obtained 
from the enrollment form and the interview survey were an-
alyzed. The frequency distributions and percentages were 
calculated for categorical data on each of the groups (CRCS 
education versus FIT). Continuous variables are reported as 
mean ± SD. Chi-square or Fisher’s exact test for categorical 
data and t test for continuous measures were used to deter-
mine any differences between groups. Potential differences in 
demographic data between participants not interviewed versus 
those interviewed were first examined. We then compared the 
FIT group with the CRCS education group for the participants 
who completed the interview survey. A significance level of 
0.05 was used for all statistical tests.
Results
A flow diagram for study participants is presented in Figure 1. 
Overall, 967 individuals aged 50 to 80 years received influenza 
vaccines at the study locations during times when the study 
was being conducted. A total of 133 individuals, mostly drawn 
from this group but also from other pharmacy customers pass-
ing by who did not get influenza vaccines, were eligible and en-
rolled in the study. A total of 95 individuals were enrolled in 
the FIT group and 38 in the CRCS education group. Follow-up 
interviews were conducted with 86 (90%) of the FIT enrollees 
and 28 (74%) of the CRCS education enrollees. The 19 indi-
viduals who could not be reached were mostly nonwhite (14 of 
19 [74%]), whereas a much smaller proportion of those inter-
viewed identified themselves as nonwhite (33 of 114 [29%]). 
The FIT intervention participants were recruited on 17 dates 
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during which 700 influenza vaccinations were administered 
to patients between 50 and 80 years of age. A total of 73 FIT 
group participants were recruited from patients in the influ-
enza vaccine line, with the remaining 22 FIT group partici-
pants recruited from customers passing by. A total of 28 CRCS 
education group participants were recruited from patients in 
the influenza vaccine line, with the remaining 5 CRCS educa-
tion group participants recruited from customers passing by. 
Therefore, the FIT group included 10% of all influenza vaccina-
tion recipients aged 50 to 80 years on the dates allocated to the 
FIT group intervention, and the CRCS education group included 
12% of all influenza vaccination recipients aged 50 to 80 years 
on the dates allocated to the CRCS education group.
Demographic characteristics of participants who com-
pleted the postintervention phone interviews are displayed in 
Table 1. Participants were mostly in their 50s and 60s, white, 
insured, and well educated. Most had received influenza vac-










Age (years), mean ± SD (min, max) 61.1 ± 8.5 (49, 77) 59.2 ± 8.1 (49, 80) 0.277
Women 19 (67.9) 45 (52.3) 0.190
Ethnicity 
Asian 6 (21.4) 7 (8.2) 0.156
White 17 (60.7) 63 (74.1)
Other/unknown 5 (17.9) 16(18.6)
Education 
High school or less 4 (14.3) 8 (10.0) (n = 80) 0.504
Some college or more 24 (85.7) 72 (90.0) (n = 80)
Health insurance (yes) 24 (85.7) 82 (95.3) 0.100
Influenza vaccine on date of CRCS intervention (yes) 25 (89.3) 64 (74.4) 0.120
Any CRCS test in past (yes) 6 (21.4) 24 (27.9) 0.624
Stool test in past (yes) 3 (10.7) 17 (19.8) 0.394
Time from enrollment date to interview (days), mean ± SD (min, max) 107.8 ± 36.0 (76, 232) 110.0 ± 26.3 (66,173) (n = 85) 0.725
Abbreviations used: CRCS, colorectal cancer screening; FIT, fecal immunochemical test. 
aItems for which sample size varies as a result of missing responses are indicated.
bP values based on Fisher’s exact or chi-square tests for categorical data and t tests for continuous data.
Figure 1. Study flow diagram for adults aged 50 to 80 years en-
rolled in the study
Abbreviations used: CRCS, colorectal cancer screening; FIT, fecal immunochemi-
cal test.





 FIT group           CRCS education group 
   95 participants    38 participants 
    
    
    
    
  
  86 participants interviewed           28 participants interviewed 
cinations in the past, but only about one-quarter had had CRCS 
in the past, with even fewer reporting having had a stool test for 
CRCS in the past. No significant demographic differences were 
found between the FIT group and the CRCS education group, 
although the overall sample sizes to make definitive compari-
sons are small.
Interviews were conducted 108 ± 26 days after study en-
rollment for the FIT group and 110 ± 36 days after enrollment 
for the CRCS education group. All participants remembered 
being enrolled in the study when they were contacted. Table 2 
shows key comparisons between responses of participants in 
the CRCS education group and the FIT group. The CRCS educa-
tion group was specifically asked to discuss CRCS with their 
“regular doctor or nurse,” which was described to participants 
as the provider who handles their primary health care issues. 
By the time of the interview, 67.9% of these individuals had 
seen their provider, with one-half of this total cohort report-
ing a CRCS discussion with their primary care clinician since 
enrolling in the study and one-third reporting that they had 
scheduled or completed a CRCS test during the time between 
enrolling in the study and completing the interview. Only 1 of 
14 participants who had not seen their provider stated that 
they had scheduled a test. In contrast, only 32.6% of FIT group 
participants reported seeing their primary care clinician, with 
only 19.8% having discussed CRCS with their clinician since 
enrolling in the study. However, 51 participants (59.3%) in 
the FIT group reported completing CRCS by any method by the 
time of their interview. Completion of FIT was independently 
confirmed for 52.2% of FIT group participants by receipt of re-
sults. Of results received, only one participant tested positive 
(abnormal) and that participant reported completing a diag-
nostic colonoscopy within 2 months of receiving the abnormal 
result from the principal investigator.
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In the CRCS education group, 23 of 28 participants 
(82.1%) found the information they received to be useful, stat-
ing that it provided new information (11 of 23 [48%]) or served 
as a reminder to them to discuss the topic with their primary 
care clinician (12 of 23 [52%]). In the FIT group, 28 of the 51 
individuals indicating that they completed CRCS (54.9%) stat-
ed that this was the first time they had ever completed a home 
CRCS test and 15 of the remaining 23 participants (65.2%) 
who had previous experience with home stool tests for CRCS 
indicated that FIT was easier to perform than previous versions 
of the test. Among the 35 FIT group participants who did not 
complete the test, only 2 of 35 (5.7%) said the reason for not 
completing it was that the instructions were too complicated. 
The most common reasons for not completing FIT were forget-
ting to complete the test and losing the kit, which was reported 
by 29% (10 of 35) and 20% (7 of 35) of these participants, 
respectively.
When asked to describe their perceptions regarding re-
ceiving CRCS education from pharmacists, participants in both 
groups were equally enthusiastic. Reasons cited for this enthu-
siasm by more than one-half of all participants were that phar-
macies are a trustworthy and convenient source for obtaining 
health information, that colon cancer is a serious health issue 
to learn about, and that having such conversations with phar-
macists would save them time with their primary care clini-
cian. Participants were equally enthusiastic about the idea of 
obtaining FIT kits from pharmacies, but only 38.6% said that 
they would be willing to pay $20 or more for such tests.
Discussion
To our knowledge, this is the first study to link the provision of 
CRCS screening activities to a pharmacy-based influenza vac-
cination program. The results indicate that pharmacy-based 
CRCS education can be successful in encouraging patients to 
discuss CRCS with their primary care clinicians but that offer-
ing FIT to patients may lead to greater increases in screening 
over a 3- to 6-month period than can be accomplished by edu-
cation alone. The interviews with study participants indicated 
a high level of acceptance of pharmacy-based CRCS interven-
tions.
The American Association of Colleges of Pharmacy has ex-
plicitly recognized the role of the pharmacist in public health in 
its educational policy statements, which state that pharmacists 
should promote “health improvement, wellness, and disease 
prevention.”14 Pharmacies are easily accessible in most com-
munities, with increased hours of operation compared with pri-
mary care practices and drop-in services that are available to 
patients on a fee-for-service basis regardless of insurance sta-
tus.15 Participants in each arm of the study were equally inter-
ested in CRCS education and the option of getting home CRCS 
tests directly from their pharmacist, citing convenience and 
trust in pharmacists as primary reasons for their enthusiasm. 
In our study, the majority of participants indicated an intention 
to obtain influenza vaccinations at their community pharmacy 










Seen your regular doctor or nurse since enrolled in study and/or got influenza vac-
cine 
Yes 19 (67.9) 28 (32.6)
 
0.002
No/uncertain 9 (32.1) 58 (67.4)
Discussed CRCS with provider since joined study and/or got influenza vaccine 
Yes 14 (50.0) 17 (19.8)
 
0.003
No 14 (50.0) 69 (80.2)
Completed or scheduled a screening test since enrolled study and/or got influenza 
vaccine 
Yes, completed 4 (14.8) (n = 27) 51 (59.3)
 
<0.0001
Yes, scheduled 5 (18.5) (n = 27) 0
No 18 (66.7) (n = 27) 34 (39.5)
Think it is a good idea and helpful for community pharmacists to educate patients 
about CRCS when they come for influenza vaccine 
Yes 24 (85.7) 81 (94.2)
 
0.220
No/uncertain/refused 4 (14.3) 5 (5.8)
Think it is a good idea and helpful for community pharmacists to offer patients home 
colon cancer screening tests when indicated 
Yes 23 (82.1) 78 (90.7)
 
0.302
No/uncertain/refused 5 (17.9) 8 (9.3)
Abbreviations used: CRCS, colorectal cancer screening.
aItems for which sample size varies as a result of missing responses are indicated.
bP values based on Fisher’s exact or chi-square tests for categorical data and t tests for continuous data.
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again in the future, suggesting that annual influenza vaccina-
tion clinics may provide good opportunities for pharmacists to 
reach a specific group of individuals with other important and 
personalized annual preventive health messages or interven-
tions such as those relating to CRCS.
All 18 community pharmacies approached agreed to par-
ticipate, and pharmacists at each site often helped with par-
ticipant recruitment for the study. However, in this study, the 
intervention was delivered by researchers (usually a pharma-
cist or a student pharmacist), and more research is required to 
determine whether this intervention could be as effective when 
delivered outside the context of a research study by community 
pharmacists. In particular, more study is needed to understand 
the resources that U.S. pharmacies and pharmacists would re-
quire to develop and incorporate such programs into their busy 
clinical practices.
Reliance on patient self-report to determine screening 
status and eligibility for FIT was a drawback of our pharmacy-
based CRCS interventions. Although concerns may exist about 
the ability of pharmacists to assess CRCS status without access 
to medical records, simple validated questions have proved 
reasonably accurate for identifying CRCS status.16–18 As with 
other point-of-care tests available in pharmacies, follow-up of 
abnormal results may also be a concern. However, an increas-
ing number of pharmacists communicate electronically with 
primary care offices regarding medications and provision of 
services such as influenza vaccinations, and it should be feasi-
ble for pharmacies to develop similar systems to communicate 
results of home CRCS tests to patients’ primary care clinicians 
as well.
Finally, although the type of FIT used in this study is ap-
proved for sale in U.S. pharmacies, it is not currently available. 
Less studied and less sensitive “throw-in-the-bowl” CRCS tests 
are available in some U.S. community pharmacies. These tests 
are not endorsed by USPSTF or the researchers. However, the 
successful marketing of such products in some regions of the 
United States indicates that a market could exist for high-sensi-
tivity home CRCS tests provided over the counter to patients in 
community pharmacies with adequate education and follow-up 
of results. To reach a large number of patients, the cost of these 
tests would likely have to be relatively low; most of participants 
in the current study indicated that they would not pay for a kit 
costing $20 or more. However, Medicare currently reimburses 
$22 for FIT; therefore, for example, pharmacies charging $20 
to $35 for one of these tests could make arrangements to have 
all or enough of the costs of the test covered in a way that in-
sured patients would not have to pay more than $20 for them 
out of pocket. In the meantime, the cost of encouraging patients 
to speak with their primary care clinicians about CRCS is most-
ly measurable in time but appears from this pilot study to have 
some potential benefit in terms of encouraging patients to get 
screening when they need it.
Limitations
The current study is limited mainly by its small sample size and 
scope. As a result of the lengthy consent process, only 1 in 10 
age-eligible adults was assessed, determined to be eligible for 
the intervention according to study criteria, and enrolled in the 
study. Diversity of the participant pool was further limited by 
the exclusion of non–English-speaking patients and patients 
with no regular source of primary care. Despite completing in-
terviews with 85.7% of enrolled participants, inability to retain 
a disproportionate subset of enrolled participants from ethnic 
minorities for the interviews may have also skewed the results. 
However, the study sample was recruited from 18 different 
sites in diverse neighborhoods and reflected a diversity of ages, 
ethnicities, and sociodemographic groups.
A second limitation is that the study design did not simulate 
usual care in the pharmacy, as community pharmacists were 
not responsible for providing the intervention or arranging 
follow-up of test results. Some patients were reluctant to talk 
with research team members not employed by the pharmacy. 
Patients may have been more accepting of the intervention if 
it was delivered by the pharmacist directly. More study will be 
needed to understand the clinical and financial incentives that 
could be put in place to encourage pharmacies and pharma-
cists to implement a program involving patient education and/
or provision of FIT kits to patients in clinical practice. As in this 
study, this service could be coupled with influenza vaccination, 
with the screening questionnaire addressing both influenza 
vaccine and CRCS appropriateness simultaneously. Alterna-
tively, a pharmacy computer system could be programmed to 
alert the pharmacist to counsel patients for whom CRCS may 
be indicated (e.g., age 50–75 years) at the time of prescription 
processing.
Finally, much of the information on screening eligibility and 
activity was obtained by self-report, which may not be reliable. 
However, among study participants contacted who discussed 
screening with their primary care clinician, very few reported 
being told by their physician or nurse that our assessment of 
screening eligibility was in error. In addition, the proportion of 
patients completing CRCS was roughly corroborated by FIT re-
sults received by the researchers from the laboratory.
conclusion
This pilot study demonstrated that providing home CRCS tests 
in the community pharmacy setting to eligible patients at the 
time of influenza vaccination can increase screening rates com-
pared with providing CRCS education only. Study participants 
were receptive to the idea of pharmacists providing CRCS in-
terventions consisting of CRCS education plus the provision of 
home CRCS tests at the time of their annual influenza vaccina-
tion activities, indicating that community pharmacies may be 
an ideal venue to increase access to CRCS and increase screen-
ing rates in diverse communities.
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